Isoprenoids and Novel Inhibitors of Mevalonate Pathway Activities

Nutritional Oncology, Second Edition

Volumn , Issue , 2006, Pages 629-644

  Mo, Huanbiao ^a   Elson, Charles E ^b  

^a TEXAS WOMAN'S UNIVERSITY   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 67651134477     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012088393-6/50094-4     Document Type: Chapter

References (245)

1. I. Adany, E.M. Yazlovitskaya, J.S. Haug, P.A. Voziyan and G. Melnykovych (1994) Differences in sensitivity to farnesol toxicity between neoplastically- and non-neoplastically-derived cells in culture. Cancer Lett 79 175-179.
2. A.A. Adjei, C. Erlichman, J.N. Davis, D.L. Cutler, J.A. Sloan, R.S. Marks, L.J. Hanson, P.A. Svingen, P. Atherton, W.R. Bishop, P. Kirschmeier and S.H. Kaufmann (2000) A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity. Cancer Res 60 1871-1877.
3. A.A. Adjei, A. Maue, L. Bruzek, R.S. Marks, S. Hillman, S. Geyer, L.J. Hanson, J.J. Wright, C. Erlichman, S.H. Kaufmann and E.E. Vokes (2003) Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer. J Clin Oncol 21 1760-1766.
4. M.K. Agarwal, M.L. Agarwal, M. Athar and S. Gupta (2004) Tocotrienolrich fraction of palm oil activates p53, modulates Bax/Bcl2 ratio and induces apoptosis independent of cell cycle association. Cell Cycle 3 205-211.
5. B. Agarwal, S. Bhendwal, B. Halmos, S.F. Moss, W.G. Ramey and P.R. Holt (1999) Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells. Clin Cancer Res 5 2223-2229.
6. M. Ameyar, M. Wisniewska and J.B. Weitzman (2003) A role for AP-1 in apoptosis: the case for and against. Biochimie 85 747-752.
7. Anonymous (1993) Lovastatin 5-year safety and efficacy study. Lovastatin Study Groups I through IV. Arch Intern Med 153 1079-1087.
8. E.A. Ariazi and M.N. Gould (1999) Identifying differential gene expression in monoterpene-treated mammary carcinomas using subtractive display. J Biol Chem 271 29286-29294.
9. E.A. Ariazi, Y. Satomi, M.J. Ellis, J.D. Haag, W. Shi, C.A. Sattler and M.N. Gould (1999) Activation of the transforming growth factor beta signaling pathway and induction of cytostasis and apoptosis in mammary carcinomas treated with the anticancer agent perillyl alcohol. Cancer Res 59 1917-1928.
10. R. Asslan, A. Pradines, G. Favre and F. Le Gaillard (1998) Tyrosine kinase-dependent modulation of 3-hydroxy-3-methylglutaryl-CoA reductase in human breast adenocarcinoma SKBR-3 cells. Biochem J 330 241-246.
11. A. Awada, F.A. Eskens, M. Piccart, D.L. Cutler, A. van der Gaast, H. Bleiberg, J. Wanders, M.N. Faber, P. Statkevich, P. Fumoleau and J. Verweij (2002) Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumours. Eur J Cancer 38 2272-2278.
12. N.I. Azrolan and P.S. Coleman (1989) A discoordinant increase in the cellular amount of 3-hydroxy-3-methylglutaryl-CoA reductase results in the loss of rate-limiting control over cholesterogenesis in a tumor cell-free system. Biochem J 258 421-425.
13. C.G. Azzoli, V.A. Miller, K.K. Ng, L.M. Krug, D.R. Spriggs, W.P. Tong, E.R. Riedel and M.G. Kris (2003) A phase I trial of perillyl alcohol in patients with advanced solid tumors. Cancer Chemother Pharmacol 51 493-498.
14. T.J. Bach (1995) Some new aspects of isoprenoid biosynthesis in plants—a review. Lipids 30 191-202.
15. H.H. Bailey, D. Levy, L.S. Harris, J.C. Schink, F. Foss, P. Beatty and S. Wadler (2002) A phase II trial of daily perillyl alcohol in patients with advanced ovarian cancer: Eastern Cooperative Oncology Group Study E2E96. Gynecol Oncol 85 464-468.
16. S. Bardon, V. Foussard, S. Fournel and A. Loubat (2002) Monoterpenes inhibit proliferation of human colon cancer cells by modulating cell cycle-related protein expression. Cancer Lett 181 187-194.
17. S. Bardon, K. Picard and P. Martel (1998) Monoterpenes inhibit cell growth, cell cycle progression, and cyclin D1 gene expression in human breast cancer cell lines. Nutr Cancer 32 1-7.
18. D. Barron and R.A. Ibrahim (1996) Isoprenylated flavonoids—a survey. Phytochem 43 921-982.
19. J. Bartek and J. Lukas (2001) Pathways governing G1/S transition and their response to DNA damage. FEBS Lett 490 117-122.
20. D.M. Beaupre, J. McCafferty-Grad, N.J. Bahlis, L.H. Boise and M.G. Lichtenfield (2003) Farnesyl transferase inhibitors enhance death receptor signals and induce apoptosis in multiple myeloma cells. Leuk Lymp 44 2123-2134.
21. L. Beck, T.J. Hosick and M. Sinensky (1988) Incorporation of a product of mevalonic acid metabolism into proteins of Chinese hamster ovary cell nuclei. J Cell Biol 107 1307-1316.
22. F. Bennis, G. Favre, F. Le Gaillard and G. Soula (1993) Importance of mevalonate-derived products in the control of HMG-CoA reductase activity and growth of human lung adenocarcinoma cell line A549. Int J Cancer 55 640-645.
23. M. Bentinger, J. Grunler, E. Peterson, E. Swiezewska and G. Dallner (1998) Phosphorylation of farnesol in rat liver microsomes: properties of farnesol kinase and farnesyl phosphate kinase. Arch Biochem Biophys 353 191-198.
24. M. Birringer, J.H. EyTina, B.A. Salvatore and J. Neuzil (2003) Vitamin E anologues as inducers of apoptosis: structure-function relation. Br J Cancer 88 1948-1955.
25. L. Blais, A. Desgagne and J. LeLorier (2000) 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Arch Intern Med 160 2363-2368.
26. L.M. Blanco-Colio, P. Justo, I. Daehn, C. Lorz, A. Ortiz and J. Egido (2003) Bcl-xL overxpression protects from apoptosis induced by HMG-CoA reductase inhibitors in murine tubular cells. Kidney Int 64 181-191.
27. L.M. Blanco-Colio, A. Villa, M. Ortego, M.A. Hernandez-Presa, A. Pascual, J.J. Plaza and J. Egido (2002) 3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation. Atherosclerosis 161 17-26.
28. E. Bossy-Wetzel, L. Bakiri and M. Yaniv (1997) Induction of apoptosis by the transcription factor c-jun. EMBO J 16 1695-1709.
29. D.L. Bradfute and R.D. Simoni (1994) Non-sterol compounds that regulate cholesterogenesis. Analogues of farnesyl pyrophosphate reduce 3-hydroxy-3-methylglutaryl-coenzyme A reductase levels. J Biol Chem 269 6645-6650.
30. C.D. Britten, E.K. Rowinsky, S. Soignet, A. Patnaik, S.L. Yao, P. Deutsch, Y. Lee, R.B. Lobell, K.E. Mazina, H. McCreery, S. Pezzuli and D. Springgs (2001) A phase I and pharmacological study of the farnesyl protein transferase inhibitor L-778,123 in patients with solid malignancies. Clin Cancer Res 7 3894-3903.
31. K. Briviba, K. Schnaebele, E. Schwertle, M. Blockhaus and G. Rechkemmer (2001) beta-Carotene inhibits growth of human colon carcinoma cells in vitro by induction of apoptosis. Biol Chem 382 1663-1668.
32. S.A. Broitman, J. Wilkinson, S. Cerda and S.K. Branch (1996) Effects of monoterpenes and mevinolin on murine colon tumor CT-26 in vitro and its hepatic “metastases” in vivo. Adv Exp Med Biol 401 111-130.
33. M.S. Brown and J.L. Goldstein (1980) Multivalent feedback regulation of HMG CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth. J Lipid Res 21 505-517.
34. M.S. Brown and J.L. Goldstein (1997) The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 89 331-340.
35. G. Brunscalalupi, S. Leoni, M.T. Mangiantini, M. Minieri, S. Spagnuolo and A. Trentlane (1985) True uncoupling between cholesterol synthesis and 3-hydroxy-3-methylglutaryl coenzyme A reductase in an early stage of liver generation. Cell Mol Biol 31 365-368.
36. J.C. Buckner, M.G. Malkin, E. Reed, T.L. Cascino, J.M. Reid, M.M. Ames, W.P. Tong, S. Lim and W.D. Figg (1999) Phase II study of antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in patients with recurrent glioma. Mayo Clin Proc 74 137-145.
37. Y.D. Burke, M.J. Stark, S.L. Roach, S.E. Sen and P.L. Crowell (1997) Inhibition of pancreatic cancer growth by the dietary isoprenoids farnesol and geraniol. Lipids 32 151-156.
38. Y.D. Burke, A.S. Ayoubi, S.R. Werner, B.C. McFarland, D.K. Heilman, B.A. Ruggeri and R.L. Crowell (2002) Effects of the isoprenoids perillyl alcohol and farnesol on apoptosis biomarkers in pancreatic cancer chemoprevention. Anticancer Res 22 3127-3134.
39. F. Caponigro, M. Casale and J. Bryce (2003) Farnesyl trnasferase inhibitiors in clinical development. Expert Opin Investig Drugs 12 943-954.
40. M.A. Carducci, M.K. Bowling, M.A. Eisenberger, V. Sinibaldi, J.W. Simons, T.L. Chen, D. Noe, L.B. Grochow and R.C. Donehower (1996) Phenylbutyrate (PB) for refractory solid tumors: a phase I clinical and pharmacologic evaluation. Proc Am Soc Clin Oncol 15 A1542.
41. S. Carnesecchi, R. Bras-Goncalves, A. Bradaia, M. Zeisel, F. Gosse, M-F. Poupan and F. Raul (2004) Geraniol, a component of plant essential oils, modulates DNA synthesis and potentiate 5-fluorouracil efficacy on human tumor xenografts. Cancer Lett 215 53-59.
42. G.L. Case, L. He, H. Mo and C.E. Elson (1995) Induction of geranyl-pyrophosphate pyrophosphatase activity by cholesterol-supperssive isoprenoids. Lipids 30 357-359.
43. C.A. Cates, R.L. Michael, K.R. Stayrook, K.A. Harvey, Y.D. Burke, S.K. Randall, P.L. Crowell and D.N. Crowell (1996) Prenylation of oncogenic human PTP (CAAX) protein tyrosine phosphatases. Cancer Lett 110 49-55.
44. R. Chakrabarti and E.G. Engleman (1991) Interrelationships between mevalonate metabolism and the mitogenic signaling pathway in T lymphocyte proliferation. J Biol Chem 266 12216-12222.
45. S.M. Chang, J.G. Kuhn, H.I. Robins, S.C. Schold, A.M. Spence, M.S. Berger, M.P. Mehta, M.E. Bozik, I. Pollack, D. Schiff, M. Gilbert, C. Rankin and M.D. Prados (1999) Phase II study of phenylacetate in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report. J Clin Oncol 17 984-990.
46. J.T. Chao, A. Gapor and A. Theriault (2002) Inhibitory effect of delta-tocotrienol. A HMG-CoA reductase inhibitor, on monocyte-endothelial cell adhesion. J Nutr Sci Vitaminol Tokyo 48 332-337.
47. H.W. Chen, A.A. Kandutsch and H.J. Heineiger (1978) The role of cholesterol in malignancy. Prog Exp Tumour Res 22 275-316.
48. H.H. Chow, D. Salazar and I.A. Hakim (2002) Pharmacokinetics of perillic acid in humans after a single dose administration of a citrus preparation rich in d-limonene content. Cancer Epidemiol Biomarkers Prev 11 1472-1476.
49. S.S. Clark, S.M. Perman, M.B. Sahin, G.J. Jenkins and J.A. Elegbede (2002) Antileukemic activity of perillyl alcohol (POH): uncoupling apoptosis from G0/G1 arrests suggests that the primary effect of POH on Bcr/Abl-transformed cells is to induce growth arrest. Leukemia 16 213-222.
50. S.S. Clark, L. Zhong, D. Filiault, S. Perman, Z. Ren, M. Gould and X. Yang (2003) Anti-leukemia effect of perillyl alcohol in Bcr/Abl-transformed cells indirectly inhibits signaling through Mek in a Ras-and Raf-independent fashion. Clin Cancer Res 9 4494-4504.
51. R.J. Clegg, B. Middleton, G.D. Bell and D.A. White (1982) The mechanism of cyclic monoterpene inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase in vivo in the rat. J Biol Chem 257 2294-2299.
52. S.J. Cohen, L. Ho, S. Ranganathan, J.L. Abbruzzese, R.K. Alpaugh, M. Beard, N.L. Lewis, S. McLaughlin, A. Rogatko, J.J. Perez-Ruixo, A.M. Thistle, T. Verhaeghe, H. Wang, L.M. Weiner, J.J. Wright, G.R. Hudes, J. Neal and N.J. Meropol (2003) Meropol Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. J Clin Oncol 21 1301-1306.
53. P.S. Coleman, L.C. Chen and L. Sepp-Lorenzino (1997) Cholesterol metabolism and tumor cell proliferation. Subcellular Biochem 28 363-435.
54. P. Coni, J. Pang, G. Pichiri-Coni, S. Hsu, P.M. Rao, S. Rajalakshmi and D.S. Sarma (1992) Hypomethylation of beta-hydroxy-beta-methyl-glutaryl coenzyme A reductase gene and its expression during hepato-carcinogenesis in the rat. Carcinogenesis 13 497-499.
55. G.C. Correll and P.A. Edwards (1994) Mevalonic acid-dependent degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase in vivo and in vitro. J Biol Chem 269 633-638.
56. P.L. Crowell, R.R. Chang, Z. Ren, C.E. Elson and M.N. Gould (1991) Selective inhibition of isoprenylation of 21–26-kDa proteins by the anticarcinogen d-limonene and its metabolites. J Biol Chem 266 17679-17685.
57. P.L. Crowell and C.E. Elson (2001) Isoprenoids, health and disease. R.E.C. Wildman (Eds) Nutraceuticals and Functional Foods New York: CRC Press 31-53.
58. P.L. Crowell, Z. Ren, S. Lin, E. Vedejs and M.N. Gould (1994) Structure-activity relationships among monoterpene inhibitors of protein isoprenylation and cell proliferation. Biochem Pharmacol 47 1405-1415.
59. M. Crul, G.J. de Klerk, M. Swart, L.J. van't Veer, D. de Jong, L. Boerrigter, P.A. Palmer, C.J. Bol, H. Tan, G.C. de Gast, J.H. Beijnen and J.H. Schellens (2002) Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol 20 2726-2735.
60. J.S. Dahiya, R.N. Strange, K.G. Bilyard, C.J. Cooksey and P.J. Garratt (1984) Two isoprenylated isoflavone phytoalexins from Cajanus cajan. Phytochemistry 23 871-874.
61. T. David-Pfeuty, F. Chakrani, K. Ory and Y. Nouvian-Dooghe (1996) Cell cycle-dependent regulation of nuclear p53 traffic occurs in one subclass of human tumor cells and in untransformed cells. Cell Growth Differ 7 1211-1225.
62. C. Denoyelle, P. Albanese, G. Uzan, L. Hong, J.P. Vannier, J. Soria and C. Soria (2003) Molecular mechanism of the anti-cancer activity of cerivastatin, an inhibitor of HMG-CoA reductase, on aggressive human breast cancer cells. Cellular Signaling 15 327-338.
63. S. De Rosa, A. De Giulio and C. Iodice (1994) Biological effects of prenylated hydroquinones: Structure-activity relationship studies in antimicrobial, brine shrimp, and fish lethality assays. J Nat Prod 57 1711-1716.
64. J.A. DiGiuseppe, L.J. Weng, K.H. Yu, S. Fu, M.B. Kastan, D. Samid and S.D. Gore (1999) Phenylbutyrate-induced G1 arrest and apoptosis in myeloid leukemia cells: structure-function analysis. Leukemia 13 1243-1253.
65. J. Dimitroulakos, S. Thai, G.H. Wasfy, D.W. hedley, M.D. Minden and L.Z. Penn (2000) Lovastatin induces a pronounced differentiation response in acute myeloid leukemias. Leuk Lymphoma 40 167-178.
66. A. Dricu, M. Wang, M. Hjertman, M. Malec, H. Blegen, J. Wejde, M. Carlberg and O. Larsson (1997) Mevalonate-regulated mechanisms in cell growth control: role of dodichyl phosphate in expression of the insulin-like growth factor-eceptor (IGF-IR) in comparison to Ras prenylation and expression of c-myc. Glycobiology 7 625-633.
67. R.E. Duncan, D. Lau, A. El-Sohemy and M.C. Archer (2004) Geraniol and b-ionone inhibit proliferation, cell cycle progression, and cyclin-dependent kinase 2 activity in MCF-7 breast cancer cells independent of effects on HMG-CoA reductase activity. Biochem Pharmacol 68 1739-1747.
68. R. Eferl and E.F. Wagner (2003) AP-1: a double-edged sword in tumorigenesis. Nature Reviews Cancer 3 859-868.
69. Y. Egozi, B. Weisz, M. Gana-Weisz, G. Ben-Baruch and Y. Kloog (1999) Growth inhibition of ras-dependent tumors in nude mice by a potent ras-dislodging antagonist. Int J Cancer 80 911-918.
70. J.A. Elegbede, R. Flores and R.C. Wang (2003) Perillyl alcohol and perillaldehyde induced cell cycle arrest and cell death in BroTo and A549 cells cultured in vitro. Life Sci 73 2831-2840.
71. C.E. Elson (1995) Suppression of mevalonate pathway activities by dietary isoprenoids: Protective roles in cancer and cardiovascular disease. J Nutr 125 1666s-1672s.
72. C.E. Elson (1996) Novel lipids and cancer: Isoprenoids and other phytochemicals. D. Heber, D. Kritchevsky (Eds) Dietary Fats, Lipids, Hormones, and Tumorigenesis New York: Plenum Publishing Corporation 71-86.
73. C.E. Elson, D.M. Peffley, P. Hentosh and H. Mo (1999) Isoprenoid-mediated inhibition of mevalonate synthesis: potential application to cancer. Proc Soc Exp Biol Med 221 294-311.
74. C.E. Elson and S.G. Yu (1994) The chemoprevention of cancer by mevalonate-derived constitutents of fruits and vegetables. J Nutr 124 607-614.
75. W. Engstrom and P.N. Schofield (1987) Expression of 3-hydroxy-3-methylglutaryl coenzyme A- reductase and LDL-receptor genes in human embryonic tumors and in normal fetal tissues. Anticancer Res 7 337-342.
76. W. Engstrom and O. Larsson (1988) The effects of glycosylation inhibitors on the proliferation of a spontaneously transformed cell line (3T6) in vitro. Cell Sci 90 447-456.
77. S.K. Erickson, A.D. Cooper, G.F. Barnard, C.M. Havel, J.A. Watson, K.R. Feingold, A.H. Moser, M. Hughes-Fulford and M.D. Siperstein (1988) Regulation of cholesterol metabolism in a slow-growing hepatoma in vivo. Biochim Biophys Acta 960 131-138.
78. F.A. Eskens, A. Awada, D.L. Cutler, M.J. de Jonge, G.P. Luyten, M.N. Faber, P. Statkevich, A. Sparreboom, J. Verweij, A.R. Hanauske and M. Piccart (2001) Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors. J Clin Oncol 19 1167-1175.
79. V.A. Fadok and P.M. Hanson (2003) Apoptosis: Giving phosphatidylserine recongition an assist—with a twist. Current Biol 13 R655-R657.
80. E. Fenig, M. Szyper-Kravitz, R. Yerushalmi, M. Lahav, M. Beery, L. Wasserman, H. Gutman and J. Nordenberg (2002) Basic fibroblast growth factor mediated growth inhibition in breast cancer cells is independent of ras signaling pathway. Oncology Rep 9 875-877.
81. N. Ferri, L. Arnaboldi, A. Orlandi, K. Yokoyama, R. Gree, A. Granata, A. Hachem, R. Paoletti, M.H. Gelb and A. Corsini (2001) Effect of S(−) perillic acid on protein prenylation and arterial smooth muscle cell proliferation. Biochem Pharmacol 62 1637-1645.
82. P. Finzer, M. Stohr, N. Seibert and F. Rosl (2003) Phenylbutyrate inhibits growth of cervical carcinoma cells independent of HPV type and copy number. J Cancer Res Clin Oncol 129 107-113.
83. J. Flach, I. Antoni, P. Villemin, C.L. Bentzen and E.J. Niesor (2000) The mevalonate/isoprenoid oathway inhibitor apomine (SR-45023A) is antiproliferative and induces apoptosis similar to famesol. Biochem Biophys Res Commun 270 240-246.
84. H. Gagnon, J. Grandmaison and R. Ibrahim (1995) Phytochemical and immunocytochemical evidence for the accumulation of 2′-hydroxylupalbigenin in lupin nodules and bacteriods. Mol Plant Microbe Interact 8 131-137.
85. M. Gana-Weisz, J. Halaschek-Wiener, B. Jansen, G. Elad, R. Haklai and Y. Kloog (2002) The Ras inhibitor S trans, trans-farnesylthiosalicylic acid chemosensitizes human tumor cells without causing resistance. Clin Cancer Res 8 555-565.
86. N. Garcia-Roman, A.M. Alvarez, M.J. Toro, A. Montes and M.J. Lorenzo (2001) Lovastatin induces apoptosis of spontaneously immortalized rat brain neuroblasts: involvement of nonsterol isoprenoid biosynthesis inhibition. Mol Cell Neurosci 17 329-341.
87. A.L. Gartel, M.S. Serfas, M. Garel, E. Goufman, G.S. Wu, W.S. El-Deiry and A.L. Tyner (1996) P21 (WAF1/CIP1) expression is induced in newly nondividing cells in diverse epithelia and during differentiation of the Caco-2 intestinal cell line. Exper Cell Res 227 171-181.
88. M.H. Gelb, F. Tamanoi, K. Yokoyama, F. Ghomashchi, K. Esson and M.N. Gould (1995) The inhibition of protein prenyltransferases by oxygenated metabolites of limonene and preillyl alcohol. Cancer Lett 91 169-175.
89. R. George and S. Goldfarb (1980) Inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in Morris hepatoma 7800 after intravenous injection of mevalonic acid. Cancer Res 40 4717-4721.
90. P.M. Ghosh, M.L. Moyer, G.E. Mott and J.I. Kreisberg (1999) Effect of cyclin E overexpression on lovastatin induced G1 arrest and RhoA inactivation in NIH3T3 cells. J Cell Biochem 74 532-543.
91. R.K. Giri, T. Parija and B.R. Das (1999) d-Limonene chemoprevention of hepatocarcinogenesis in AKR mice: inhibition of c-jun and c-myc. Oncol Rep 6 1123-1127.
92. L. Girnita, M. Wang, Y. Xie, G. Nilsson, A. Dricu, J. Wejde and O. Larsson (2000) Inhibition of N-linked glycosylation down-regulates insulin-like growth factor-1 receptor at the cell surface and kills Ewing's sarcoma cells: Therapeutic implications. Anti-Cancer Drug Design 15 67-72.
93. J.L. Goldstein and M.S. Brown (1990) Regulation of the mevalonate pathway. Nature (Lond) 343 425-430.
94. S.M. Graham, A.D. Cox, G. Drivas, M.G. Rush, P. D'Eustachio and C.J. Der (1994) Aberrant function of the Ras related protein TC21/R-Ras2 triggers malignant transformation. Mol Cell Biol 14 4108-4115.
95. J. Gray-Bablin, S. Rao and K. Keyomarsi (1997) Lovastatin induction of cyclin-dependent kinase inhibitors in human breast cells occurs in a cell cycle-independent fashion. Cancer Res 57 604-609.
96. R.G. Gregg, J.R. Sabine and P.A. Wilce (1982) Regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in rat liver and Morris hepatoma 5123C, 9618A and 5123tc. Biochem J 204 457-462.
97. J.M. Gudas, H. Nguyen, T. Li, L. Sadzewicz, R. Robey, K. Wosikowski and K.H. Cowan (1996) Drug-resistant breast cancer cells frequently retain expression of a functional wild-type p53 protein. Carcinogenesis 17 1417-1427.
98. N. Guthrie, A. Gapor, A.E. Chambers and K.K. Carroll (1997) Inhibition of proliferation of estrogen receptor-negative MDA-MB-435 and-positive MCF-7 human breast cancer cells by palm oil tocotrienols and tamoxifen, alone and in combination. J Nutr 127 S544-S548.
99. S.M. Hahn, E.J. Bernhard, W. Regine, M. Mohiuddin, D.G. Haller, J.P. Stevenson, D. Smith, B. Pramanik, J. Tepper, T.F. DeLaney, K.D. Kiel, B. Morrison, P. Deutsch, R.J. Muschel and W.G. McKenna (2002) A Phase I trial of the farnesyltransferase inhibitor L-778,123 and radiotherapy for locally advanced lung and head and neck cancer. Clin Cancer Res 8 1065-1072.
100. J.D. Hainsworth, W.J. Lennington and F.A. Greco (2000) Overexpression of Her-2 in patients with poorly differentiated carcinoma or poorly differentiated adenocarcinoma of unknown primary site. J Clin Oncol 18 632-635.
101. R. Haklai, M.G. Weisz, G. Elad, A. Paz, D. Marciano, Y. Egozi, G. Ben-Baruch and Y. Kloog (1998) Dislodgment and accelerated degradation of Ras. Biochemistry 37 1306-1314.
102. P. Haluska, G. Dy and A. Adjei (2002) Farnesyl transferase inhibitors as anticancer agents. Eur J Cancer 38 1685-1700.
103. M. Hamada, K. Nishio, M. Doe, Y. Usuki and T. Tanaka (2002) Farnesylpyridinium, an analog of isoprenoid farnesol, induces apoptosis but suppresses apoptotic body formation in human promyelocytic leukemia cells. FEBS Lett 514 250-254.
104. J.F. Hancock, A.I. Magee, J.E. Childs and C.J. Marshall (1989) All ras proteins are polyisoprenylated but only some are palmitoylated. Cell 57 1167-1177.
105. V.C. Hannah, J. Ou, A. Luong, J.L. Goldstein and M.S. Brown (2001) Unsaturated fatty acids down-regulate srebp isoforms 1a and 1c by two mechanisms in HEK-293 cells. J Biol Chem 276 4365-4372.
106. J.W. Harbour and D.C. Dean (2000) Rb function in cell-cycle regulation and apoptosis. Nature Cell Biol 2 E65-E67.
107. L.E. Harrison, D.C. Wojciechowicz, M.F. Brennan and P.B. Paty (1998) Phenylacetate inhibits isoprenoid biosynthesis and suppresses growth of human pancreatic carcinoma. Surgery 124 541-550.
108. J.S. Haug, C.M. Goldner, E.M. Yazlovitskaya, P.A. Voziyan and G. Melnykovych (1994) Directed cell killing (apoptosis) in human lymphoblastoid cells incubated in the prsence of farnesol: Effect of phosphatidylcholine. Biochim Biophys Acta 1223 133-140.
109. L. He, H. Mo, S. Hadisusilo and C.E. Elson (1997) Isoprenoids suppress the growth of murine B16 melanomas in vitro and in vivo. J Nutr 127 668-674.
110. I. Hellstrom, G. Goodman, J. Pullman, Y. Yang and K.E. Hellstrom (2001) Overexpression of HER-2 in ovarian carcinomas. Cancer Res 61 2420-2423.
111. F. Hemming (1983) The biosynthesis of polyisoprenoid chains. Biochem Soc Trans 11 497-503.
112. J. Hempstock, J.P. Kavanagh and N.J. George (1998) Growth inhibition of prostate cell lines in vitro by phyto-oestrogen. Br J Urol 82 560-563.
113. P. Hentosh, S.H. Yuh, C.E. Elson and D.M. Peffley (2001) Sterol-independent regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in tumor cells. Mol Carcinog 32 154-166.
114. R.J. Hohl and K. Lewis (1995) Differential effects of monoterpenes and lovastatin on RAS processing. J Biol Chem 270 17508-17512.
115. S.A. Holstein and R.J. Hohl (2003) Monoterpenen regulation of Ras and Ras-related protein expression. J Lipid Res 44 1209-1215.
116. S.A. Holstein, C.L. Wohlford-Lenane and R.J. Hohl (2002) Isoprenoids influence expression of Ras and Ras-related proteins. Biochemistry 41 13698-13704.
117. S.A. Holstein, C.L. Wohlford-Lenane and R.J. Hohl (2002) Consequences of mevalonate depletion. Differential transcriptional, translational, and post-translational up-regulation of Ras, Rapla, RhoA, and RhoB. J Biol Chem 277 10678-10682.
118. J.D. Horton, J.L. Goldstein and M.S. Brown (2002) SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 109 1125-1131.
119. X. Hua, A. Nohturfft, J.L. Goldstein and M.S. Brown (1996) Sterol resistance in CHO cells traced to point mutation in SREBP cleavage-activating protein. Cell 87 415-426.
120. G.R. Hudes, C.E. Szarka, A. Adams, S. Ranganathan, R.A. McCauley, L.M. Weiner, C.J. Langer, S. Litwin, G. Yeslow, T. Halberr, M. Qian and J.M. Gallo (2000) Phase I pharmacokinetic trial of perillyl alcohol (NSC 641066) in patients with refractory solid malignancies. Clin Cancer Res 6 3071-3080.
121. C.J. Hutchison, J.M. Bridger, L.S. Cox and I.R. Kill (1994) Weaving a pattern from disparate threads: lamin function in nuclear assembly and DNA replication. J Cell Sci 107 3259-3269.
122. A.M. Janssen, J.J.C. Scheffer and A. Baerheim-Svendsen (1987) Antimicrobial activities of essential oils. A 1976–1986 literature review of possible applications Pharm Weekbl. Sci Ed 7 193-197.
123. R.L. Jirtle, J.D. Haag, E.A. Ariazi and M.N. Gould (1993) Increased mannose 6-phosphate/insulin-like growth factor II receptor and transforming growth factor β1 levels during monoterpene-induced regression of mammary tumors. Cancer Res 53 3849-3852.
124. S.R. Johnston, T. Hickish, P. Ellis, S. Houston, L. Kelland, M. Dowsett, J. Salter, B. Michiels, J.J. Perez-Ruixo, P. Palmer and A. Howes (2003) Phase II study of the efficacy and tolerability of two dosing regimens of the farmesyl transferase inhibitor, R115777, in advanced breast cancer. J Clin Oncol 21 2492-2499.
125. J.E. Karp, J.E. Lancet, S.H. Kaufmann, D.W. End, J.J. Wright, K. Bol, I. Horak, M.L. Tidwell, J. Liesveld, T.J. Kottke, D. Ange, L. Buddharaju, I. Gojo, W.E. Highsmith, R.T. Belly, R.J. Hohl, M.E. Rybak, A. Thibault and J. Rosenblatt (2001) Clinical and biologic activity of the famesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood 97 3361-3369.
126. S. Kawata, N. Takaishi, T. Nagase, N. Ito, Y. Matsuda and S. Tamura (1990) Increase in the active form of 3-hydroxy-3-methylglutaryl coenzyme A reductase in human hepatocellular carcinoma: possible mechanism for alteration of cholesterol bio synthesis. Cancer Res 50 3270-3273.
127. S. Kawata, E. Yamasaki, T. Nagase, Y. Inui, N. Ito, Y. Matsuda, M. Inada, S. Tamura, S. Noda, Y. Imai and Y. Matsuzawa (2001) Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A radomized controlled trial. Br J Cancer 84 886-891.
128. W.S. Kim, M.M. Kim, H.J. Choi, S.S. Yoon, M.H. Lee, K. Park, C.H. Park and W.K. Kang (2001) Phase II study of high-dose lovastatin in patients with advanced gastric adenocarcinoma. Invest New Drugs 19 81-83.
129. K.D. Klepzig, E.B. Smalley and K.F. Raffa (1996) Combined chemical defenses against an insect-fungal complex. J Chem Ecol 22 1367-1388.
130. H.P. Koeffler, C. Miller, M.A. Nicolson, J. Ranyard and R.A. Bosselman (1986) Increased expression of p53 protein in human leukemia cells. Proc Natl Acad Sci USA 83 4035-4039.
131. N.E. Kotake-Nara, S.J. Kim, M. Kobori, K. Miyashita and A. Nagao (2002) Acyclo-retinoic acid induces apoptosis in human prostate cancer cells. Anticancer Res 22 689-696.
132. P.W. Laird and R. Jaenisch (1994) DNA methylation and cancer. Hum Mol Genet 3 1487-1495.
133. J. Larner, J. Jane, E. Laws, R. Packer, C. Myers and M. Shaffrey (1998) A phase I–II trial of lovastatin for anaplastic astrocytoma and glioblastoma multiforme. Am J Clin Oncol 21 579-583.
134. O. Larsson (1993) Cell cycle-specific growth inhibition of human breast cancer cells induced by metabolic inhibitors. Glycobiology 3 475-479.
135. O. Larsson (1994) Effects of isoprenoids on growth of normal human mammary epithelial cells and breast cancer cells in vitro. Anticancer Res 14 123-128.
136. S.J. Lee, M.J. Ha, J. Lee, P. Nguyen, Y.H. Choi, F. Pirnia, W.K. Kang, X.F. Wang, S.J. Kim and J.B. Trepel (1998) Inhibition of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase pathway induces p53-independent transcriptional regulation of p21 (WAF1/CIP1) in human prostate carcinoma cells. J Biol Chem 273 10618-10623.
137. Z. Li, Y. Wang and B. Mo (2002) The effects of carotenoids on the proliferation of human breast cancer cell and gene expression of bcl-2. Zhonghua Yufang Yixue Zazhi 36 254-257.
138. G. Liu, K. Oettel, H. Bailey, L. Van Ummersen, K. Tutsch, M.J. Staab, D. Horvath, D. Alberti, R. Arzoomanian, H. Rezazadeh, J. McGovern, E. Robinson, D. DeMets and G. Wilding (2003) Phase II trial of perillyl alcohol (NSC 641066) administered daily in patients with metastatic androgen independent prostate cancer. Invest New Drugs 21 367-372.
139. J-R. Liu, B.-Q. Chen, B-F. Yang, H-W. Dong, C-H. Sun, Q. Wang, G. Song and Y-Q. Song (2004) Apoptosis of human gastric adenocarcinoma cells induced by β-ionone. World J Gastroenterol 10 348-351.
140. J-R. Liu, B-F. Yang, B-Q. Chen, Y-M. Yang, H-W. Dong and Y-Q. Song (2004) Inhibition of β-ionone on SGC-7901 cell proliferation and upregulation of metalloproteinases-1 and-2 expression. World J Gastroenterol 10 167-171.
141. J. Lukas, J. Bartkova and J. Bartek (1996) Convergence of mitogenic signalling cascades from diverse classes of receptors at the cyclin D-cyclin-dependent kinase-pRb-controlled G1 checkpoint. Mol Cell Biol 16 6917-6925.
142. M. Marcelli, G.R. Cunningham, S.J. Haidacher, S.J. Padayatty, L. Sturgis, C. Kagan and L. Denner (1998) Caspase-7 is activated during lovastatin-induced apoptosis of the prostate cancer cell line LNCaP. Cancer Res 58 76-83.
143. D. Marciano, G. Ben-Baruch, M. Marom, Y. Egozi, R. Haklai and Y. Kloog (1995) Farnesyl derivatives of rigid carboxylic acids-inhibitors of ras-dependent cell growth. J Med Chem 38 1267-1272.
144. J. Martinez-Gonzalez, M. Vinals, F. Vidal, V. Llorente-Cortes and L. Badimon (1997) Mevalonate deprivation impairs IGF-I/insulin signaling in human vascular smooth muscle cells. Atherosclerosis 135 213-223.
145. J.A. McAnally, M. Jung and H. Mo (2003) Farnesyl-O-acetylhydroquinone and geranyl-O-acetylhydroquinone suppress the proliferation of murine B16 melanoma cells, human prostate and colon adenocarcinoma cells, human lung carcinoma cells, and human leukemia cells. Cancer Lett 202 181-192.
146. M.F. McCarty (2001) Suppression of dolichol synthesis with isoprenoids and statins may potentiate the cancer-retardant efficacy of IGF-I down-regulation. Med Hypotheses 56 12-16.
147. B.S. McIntyre, K.P. Briski, A. Gapor and P.W. Sylvester (2000) Antiproliferative and apoptotic effects of tocopherols and tocotrienols on preneoplastic and neoplastic mouse mammary epithelial cells. Proc Soc Exp Biol Med 224 292-301.
148. S.M. Meadows, D. Mulkerin, J. Berlin, H. Bailey, J. Kolesar, D. Warren and J.P. Thomas (2002) Phase II trial of perillyl alcohol in patients with metastatic colorectal cancer. Int J Gastrointest Cancer 32 125-128.
149. T.E. Meigs, D.S. Roseman and R.D. Simoni (1996) Regulation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase degradation by the nonsterol mevalonate metabolite farnesol in vivo. J Biol Chem 271 7916-7922.
150. T.E. Meigs and R.D. Simoni (1997) Farnesol as a regulator of HMG-CoA reductase degradation: characterization and role of farnesyl pyrophosphatase. Arch Biochem Biophys 345 1-9.
151. J.J. Mills, R.S. Chari, I.J. Boyer, M.N. Gould and R.L. Jirtle (1995) Induction of apoptosis in liver tumors by the monoterpene perillyl alcohol. Cancer Res 55 979-983.
152. M.D. Minden, J. Dimitroulakos, D. Nohynek and L.Z. Penn (2001) Lovastatin induced control of blast cell growth in an elderly patient with acute myeloblastic leukemia. Leuk Lymphoma 40 659-662.
153. K. Miquel, A. Pradines and G. Favre (1996) Farnesol and geranylgeraniol induce actin cytoskeleton disorganization and apoptosis in A549 lung adenocarcinoma cells. Biochem Biophys Res Commun 225 869-876.
154. K. Miquel, A. Pradines, F. Terce, S. Selmi and G. Favre (1998) Competitive inhibition of choline phosphotransferase by geranylgeraniol and farnesol inhibits phosphatidylcholine synthesis and induces apoptosis in human lung adenocarcinoma A549 cells. J Biol Chem 273 26179-26186.
155. K. Miyazawa, M. Yaguchi, K. Funato, A. Gotoh, Y. Kawanishi, Y. Nishizawa, A. You and K. Ohyashiki (2001) Apoptosis/differentiation-inducing effects of vitamin K2 on HL-60 cells: dichomotous nature of vitamin K2 in leukemia cells. Leukemia 15 1111-1117.
156. H. Mo and C.E. Elson (1999) Apoptosis and cell-cycle arrest in human and murine tumor cells are initiated by isoprenoids. J Nutr 129 804-813.
157. H. Mo, D.M. Peffley and C.E. Elson (1999) Targeting the action of isoprenoids and related phytochemicals to tumors. D. Heber, G.L. Blackburn, V.L.W. Go (Eds) Nutritional Oncology New York: Academic Press 379-391.
158. H. Mo, D. Tatman, M. Jung and C.E. Elson (2000) Farnesyl anthranilate suppresses the growth, in vitro and in vivo, of murine B16 melanomas. Cancer Lett 157 143-153.
159. F.S. Moreno, M.R. Rossiello, S. Manjeshwar, R. Nath, P.M. Rao, S. Rajalakshmi and S.R. Sarma-Dittakavi (1995) Effect of beta-carotene on the expression of 3-hydroxy-3-methylglutaryl coenzyme A reductase in rat liver. Cancer Lett 96 201-208.
160. S. Morgan-Meadows, S. Dubey, M. Gould, K. Tutsch, R. Marnocha, R. Arzoomanin, D. Alberti, K. Binger, C. Feierabend, J. Volkman, S. Ellingen, S. Black, M. Pomplun, G. Wilding and H. Bailey (2003) Phase I trial of perillyl alcohol administered four times daily continuously. Cancer Chemother Pharmacol 52 361-366.
161. J.R. Murren, G. Pizzorno, S.A. DiStasio, A. McKeon, K. Peccerillo, A. Gollerkari, W. McMurray, B.A. Burtness, T. Rutherford, X. Li, P.T. Ho and A. Sartorelli (2002) Phase I study of perillyl alcohol in patients with refractory malignancies. Cancer Biol Ther 1 130-135.
162. T. Mutoh, T. Kumano, H. Nakagawa and M. Kuriyama (1999) Involvement of tyrosine phosphorylation in HMG-CoA reductase inhibitor-induced cell death in L6 myoblasts. FEBS Lett 444 85-89.
163. K. Nesaretnam, S. Dorasamy and P.D. Darbre (2000) Tocotrienols inhibit growth of ZR-75-1 breast cancer cells. Internat J Food Sci Nutr 51 S95-S103.
164. K. Nesaretnam, R. Stephen, R. Dils and P. Darbre (1998) Tocotrienols inhibit the growth of human breast cancer cells irrespective of estrogen receptor status. Lipids 33 879-892.
165. H. Oda, B.L. Kasiske, M.P. O'Donnell and W.F. Keane (1999) Effects of lovastatin on expression of cell cycle regulatory proteins in vascular smooth muscle cells. Kidney Int 71 S202-S205.
166. T.F. Osborne (2000) Sterol regulatory element-binding proteins (SREBPs): key regulators of nutritional homeostasis and insulin action. J Biol Chem 275 32379-32382.
167. P. Palozza, S. Serini, A. Torsello, N. Maggiano, M. Angelini, A. Boninsegna, F. Di-Nicuolo, F.O. Ranelletti and G. Calviello (2002) Induction of cell cycle arrest and apoptosis in human colon adenocarcinoma cell lines by beta-carotene through down-regulation of cyclin A and Bcl-2 family proteins. Oxford 23 11-18.
168. P. Palozza, S. Serini, A. Torsello, A. Boninsegna, V. Covacci, N. Maggiano, F.O. Ranelletti, F.I. Wolf and G. Calviello (2002) Regulation of cell cycle progression and apoptosis by beta-carotene in undifferentiated and differentiated HL-60 leukemia cells: Possible involvement of a redox mechanism. Internat J Cancer 97 593-600.
169. P.W. Pare and J.H. Tumlinson (1997) De novo biosynthesis of volatiles induced by insect herbivory in cotton plants. Plant Physiol 114 1161-1167.
170. C. Park, I. Lee and W.K. Kang (2001) Lovastatin-induced E2F-1 modulation and its effect on prostate cancer cell death. Carcinogenesis 22 1727-1731.
171. W.H. Park, Y.Y. Lee, E.S. Kim, J.G. Seol, C.W. Lung, C.C. Lee and B.K. Kim (1999) Lovastatin-induced inhibition of HL-60 cell proliferation via cell cycle arrest and apoptosis. Anticancer Res 19 3133-3140.
172. C. Parker, P.A. Whittaker, B.A. Usmani, M.S. Lakshmi and G.V. Sherbet (1994) Induction of 18A2/mts1 gene expression and its effects on metastasis and cell cycle control. DNA Cell Biol 13 1021-1028.
173. R.A. Parker, B.C. Pearce, R.W. Clark, D.A. Gordan and J.J.K. Wright (1993) Tocotrienols regulate cholesterol production in mammalian cells by post-transcriptional suppression of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J Biol Chem 268 11230-11238.
174. A. Patnaik, S.G. Eckhardt, E. Izbicka, A.A. Tolcher, L.A. Hammond, C.H. Takimoto, G. Schwartz, H. McCreery, A. Goetz, M. Mori, K. Terada, L. Gentner, M.E. Rybak, H. Richards, S. Zhang and E.K. Rowinsky (2003) A phase I, pharmacokinetic, and biological study of the farnesyltransferase inhibitor tipifarnib in combination with gemcitabine in patients with advanced malignancies. Clin Cancer Res 9 4761-4771.
175. B.C. Pearce, R.A. Parker, M.E. Deason, D.D. Dischino, E. Gillespie, A.A. Qureshi, K. Volk and J.J. Wright (1994) Inhibitors of cholesterol biosynthesis. 2. Hypocholesterolemic and antioxidant activities of benzopyran and tetrahydronaphthalene analogues of the tocotrienols. J Med Chem 37 526-541.
176. D.M. Peffley and A.K. Gayen (1997) Inhibition of squalene synthase but not squalene cyclase prevents mevalonate-mediated suppression of 3-hydroxy-3-methylglutaryl coenzyme A reductase synthesis at a posttranscriptional level. Arch Biochem Biophys 337 251-260.
177. D.M. Peffley and A.K. Gayen (2003) Plant-derived monoterpenes suppress hamster kidney cell 3-hydroxy-3-methylglutaryl coenzyme a reductase synthesis at the post-transcriptional level. J Nutr 133 38-44.
178. D. Perez-Sala, B.A. Gilbert, R.R. Rando and F.J. Canada (1998) Analogs of farnesylcysteine induce apoptosis in HL-60 cells. FEBS Lett 426 319-324.
179. S.C. Piscitelli, A. Thibault, W.D. Figg, A. Tompkins, D. Headlee, R. Lieberman, D. Samid and C.E. Myers (1995) Disposition of phenylbutyrate and its metabolites, phenylacetate and phenylacetylglutamine. J Clin Pharmacol 35 368-373.
180. C.J. Punt, L. van Maanen, C.J. Bol, W.F. Seifert and D.J. Wagener (2001) Phase I and pharmacokinetic study of the orally administered farnesyl transferase inhibitor R115777 in patients with advanced solid tumors. Anticancer Drugs 12 193-197.
181. L. Rahalison, M. Benathan, M. Monod, E. Frenk, M.P. Gupta, P.N. Solis, N. Fuzzati and K. Hostettmann (1995) Antifungal principles of Baccharis pedunculata. Planta Med 61 360-362.
182. S. Rao, M. Lowe, T.W. Herliczek and K. Keyomarsi (1998) Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53. Oncogene 17 2393-2402.
183. B.S. Reddy, C.X. Wang, H. Samaha, R. Lubet, V.E. Steele, G.J. Kelloff and C.V. Rao (1997) Chemoprevention of colon carcinogenesis by dietary perillyl alcohol. Cancer Res 57 420-425.
184. Z. Ren, C.E. Elson and M.N. Gould (1997) Inhibition of type I and type II geranylgeranyl-protein transferases by the monoterpene perillyl alcohol in NIH3T3 cells. Biochem Pharmacol 54 113-120.
185. H. Reuveni, S. Klein and A. Levizki (2003) The inhibition of ras farnesylation leads to an increase in p27Kip1 and G1 cell cycle arrest. Eur J Biochem 270 2759-2772.
186. A. Rioja, A.R. Pizzey, C.M. Marson and N.S. Thomas (2000) Preferential induction of apoptosis of leukaemic cells by farnesol. FEBS Lett 467 291-295.
187. G.H. Ripple, M.N. Gould, R.Z. Arzoomanian, D. Alberti, C. Feierabend, K. Simon, K. Binger, K.D. Tutsch, M. Pomplun, A. Wahamaki, R. Marnocha, G. Wilding and H.H. Bailey (2000) Phase I clinical and pharmacokinetic study of perillyl alcohol administered four times a day. Clin Cancer Res 6 390-396.
188. G.H. Ripple, M.N. Gould, J.A. Stewart, K.D. Tutsch, R.Z. Arzoomanian, D. Alberti, C. Feierabend, M. Pomplun, G. Wilding and H.H. Bailey (1998) Phase I clinical trial of perillyl alcohol administered daily. Clin Cancer Res. 4 1159-1164.
189. M.R. Rossiello, P.M. Rao, S. Rajalakshmi and D.S. Sarma (1994) Similar patterns of hypomethylation in the beta-hydroxy-beta-methylglutaryl coenzyme A reductase gene in hepatic nodules induced by different carcinogens. Mol Carcinog 10 237-245.
190. J.C. Sacchettini and C.D. Poulter (1997) Creating isoprenoid diversity. Science 277 1788-1789.
191. C.S. Sadof and G.G. Grant (1997) Monoterpene composition of Pinus sylvestris varieties resistant and susceptible to Dioryctria zimmermani. J Chem Ecol 23 1917-1927.
192. M.B. Sahin, S.M. Perman, G. Jenkins and S.S. Clark (1999) Perillyl alcohol selectively induces G0/G1 arrest and apoptosis in Bcr/Abl-transformed myeloid cell lines. Leukemia 13 1581-1591.
193. K. Saito, T. Okabe, Y. Inamori, H. Tsujibo, Y. Miyake, K. Hiraoka and N. Ishida (1996) The biological properties of monoterpenes. Hypotensive effects on rats and antifungal activities on plant pathogenic fungi of monoterpenes. Mokuzai Gakkaishi 42 677-680.
194. M. Sakai, M. Okabe, M. Yamasaki, H. Tachibana and K. Yamada (2004) Induction of apoptosis by tocotrienol in rat hepatoma dRLh-84 cells. Anticancer Res 24 1683-1688.
195. D. Samid, Z. Ram, W.R. Hudgins, S. Shack, L. Liu, S. Walbridge, E.H. Oldfield and C.E. Myers (1994) Selective activity of phenylacetate against malignant gliomas: resemblance to fetal brain damage in phenylketonuria. Cancer Res 54 891-895.
196. Y. Satomi, S. Miyamoto and M.N. Gould (1999) Induction of AP-1 activity by perillyl alcohol in breast cancer cells. Carcinogenesis 20 1957-1961.
197. W.R. Schafer, R. Kim, R. Sterne, J. Thorner, S.H. Kim and J. Rine (1989) Genetic and pharmacological suppression of oncogenic mutations in ras genes of yeast and humans. Science 245 379-385.
198. D.C. Schwenke (2002) Does lack of tocopherols and tocotrienols put women at increased risk of breast cancer? J Nutr Biochem 13 2-20.
199. N. Sever, B-L. Song, D. Yabe, J.L. Goldstein, M.S. Brown and R.A. DeBose-Boyd (2003) Insig-dependent ubiquitination and degradation of mammalian 3-hydroxy-3-methylglutaryl-CoA reductase stimulated by sterols and geranylgeraniol. J Biol Chem 278 52479-52490.
200. S. Sharma, N. Kemeny, D.P. Kelsen, D. Ilson, E. O'Reilly, S. Zaknoen, C. Baum, P. Statkevich, E. Hollywood, Y. Zhu and L.B. Saltz (2002) A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan. Ann Oncol 13 1067-1071.
201. S. Shah, A. Gapor and P.W. Sylvester (2003) Role of caspase-8 activation in mediating vitamin E-induced apoptosis in murine mammary cancer cells. Nutr Cancer 45 236-246.
202. W. Shi and M.N. Gould (2002) Induction of cytostasis in mammary carcinoma cells treated with the anticancer agent perillyl alcohol. Carcinogenesis 23 131-142.
203. H. Shimano, J.D. Horton, R.E. Hammer, I. Shimomura, M.S. Brown and J.L. Goldstein (1996) Overproduction of cholesterol and fatty acids causes massive liver enlargement in transgenic mice expressing truncated SREBP-1a. J Clin Invest 98 1575-1584.
204. H. Shimano, J.D. Horton, I Shimomura, R.E. Hammer, M.S. Brown and J.L. Goldstein (1997) Isoform 1c of sterol regulatory element binding protein is less active than isoform 1a in livers of transgenic mice and in cultured cells. J Clin Invest 99 846-854.
205. I. Shimomura, H. Shimano, J.D. Horton, J.L. Goldstein and M.S. Brown (1997) Differential expression of exons 1a and 1c in mRNAs for sterol regulatory element binding protein-1 in human and mouse organs and cultured cells. J Clin Invest 99 838-845.
206. S.M. Shoff, M. Grummer, M.B. Yatvin and C.E. Elson (1991) Concentration-dependent increase in murine P388 and B16 population doubling time by the acyclic monoterpene geraniol. Cancer Res 51 37-42.
207. M-C. Shun, W. Yu, A. Gapor, R. Parsons, J. Atkinson, B.G. Sanders and K. Kline (2004) Pro-apototic mechanisms of action of a novel vitamin E analog (α-TEA) and a naturally occurring form of vitamin E (δ-tocotrienol) in MDA-MB-435 human breast cancer cells. Nutr Cancer 48 95-105.
208. J.R. Sindermann, A. Schmidt, G. Breithardt and E. Buddecke (2001) Lovastatin controls signal transduction in vascular smooth muscle cells by modulating phosphorylation levels of mevalonate-independent pathways. Basic Res Cardiol 96 283-289.
209. M.D. Siperstein and V.M. Fagan (1964) Deletion of the cholesterolnegative feedback system in liver tumors. Cancer Res 24 1108-1115.
210. K.S. Smalley and T.G. Eisen (2002) Farnesyl thiosalicylic acid inhibits the growth of melanoma cells through a combination of cytostatic and proapoptotic effects. Int J Cancer 98 514-522.
211. K.R. Stayrook, J.H. Mckinzie, Y.D. Burke, Y.A. Burke and P.L. Crowell (1997) Induction of the apoptosis-promoting protein BAK by perillyl alcohol in pancreatic ductal adenocarcinoma relative to untransformed ductal epithelial cells. Carcinogenesis 18 1655-1658.
212. J.V. Swinnen, H. Heemers, L. Deboel, F. Foufelle, W. Heyns and G. Verhoeven (2000) Simulation of tumor-associated fatty acid synthase expression by growth factor activation of the sterol regulatory element-binding protein pathway. Oncogene 19 5173-5181.
213. P.W. Sylvester and S.J. Shah (2005) Mechanisms mediating the antiproliferative and apoptotic effects of vitamin E in mammary cancer. Front Biosci 10 699-709.
214. S. Tahara, Y. Katagiri, J.L. Ingham and J. Mizutani (1994) Prenylated flavonoids in the roots of yellow lupin. Phytochemistry 36 1261-1271.
215. K. Takahashi and G. Loo (2004) Disruption of mitochondria during tocotrienol-induced apoptosis in MDA-MB-231 human breast cancer cells. Biochem Pharmacol 67 315-324.
216. F. Tamanoi, C.L. Gau, C. Jiang, H. Edamatsu and J. Kato-Stankiewicz (2001) Protein farnesylation in mammalian cells: effects of farnesyltransferase inhibitors on cancer cells. Cell Mol Life Sci 58 1636-1649.
217. D. Tatman and H. Mo (2002) Volatile isoprenoid constituents of fruits, vegetables and herbs cumulatively suppress the proliferation of murine B16 melanoma and human HL-60 leukemia cells. Cancer Lett 175 129-139.
218. A. Thibault, M.R. Cooper, W.D. Figg, D.J. Venzon, A.O. Sartor, A.C. Tompkins, M.S. Weinberger, D.J. Headlee, N.A. McCall, D. Samid and C.E. Meyers (1994) A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer. Cancer Res 54 1690-1694.
219. A. Thibault, D. Samid, M.R. Cooper, W.D. Figg, A.C. Tompkins, N. Patronas, D.J. Headlee, D.R. Kohler, D.J. Venzon and C.E. Myers (1995) Phase I study of phenylacetate administered twice daily to patients with cancer. Cancer 75 2932-2938.
220. A. Thibault, D. Samid, A.C. Tompkins, W.D. Figg, M.R. Cooper, R.J. Hohl, J. Trepel, B. Liang, N. Patronas, D.J. Venzon, E. Reed and C.E. Myers (1996) Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res 2 483-491.
221. C. Ukomadu and A. Dutta (2003) Inhibition of cdk2 activating phosphorylation by mevastatin. J Biol Chem 278 4840-4846.
222. C. Ukomadu and A. Dutta (2003) p21-dependent inhibition of colon cancer cell growth by mevastatin is independent of inhibition of G1 cyclin-dependent kinase. J Biol Chem 278 43586.
223. H. Ura, T. Obara, R. Shudo, A. Itoh, S. Tanno, T. Fujii, N. Nishino and Y. Kohgo (1998) Selective cytotoxicity of farnesylamine to pancreatic carcinoma cells and Ki-ras-transformed fibroblasts. Mol Carcinog 21 93-99.
224. D.M. Vigushin, G.K. Poon, A. Boddy, J. English, G.W. Halbert, C. Pagonis, M. Jarman and R.C. Coombes (1998) Phase I and pharmacokinetic study of d-limonene in patients with advanced cancer: Cancer Research Campaign Phase I/II Clinical Trials Committee. Cancer Chemother Pharmacol 42 111-117.
225. M. Vitale, T. DiMatola, G. Rossi, C. Laezza, G. Fenzl and M. Bifulco (1999) Prenyltransferase inhibitors induce apoptosis in proliferating thyroid cells through a p53-independent, CrmA-sensitive, and capase-3-like protease-dependent mechanism. Endocrinol 14 698-704.
226. P.A. Voziyan, C.M. Goldner and G. Melnykovych (1993) Farnesol inhibits phosphatidylcholine biosynthesis in cultured cells by decreasing cholinephosphotransferase activity. Biochem J 295 757-762.
227. P.A. Voziyan, J.S. Haug and G. Melnykovych (1995) Mechanism of farnesol cytotoxicity: further evidence for the role of PKC-dependent signal transduction in farnesol-induced apoptotic cell death. Biochem Biophys Res Commun 212 479-486.
228. F. Vrtovsnik, S. Couette, D. Prie, D. Lallemand and G. Friedlander (1997) Lovastatin-induced inhibition of renal epithelial tubular cell proliferation involves a p21ras activated, AP-1-dependent pathway. Kidney Int 52 1016-1027.
229. A. Wachtershauser, B. Akoglu and J. Stein (2001) HMG-CoA reductase inhibitor mevastatin enhances the growth inhibitory effect of butyrate in the colorectal carcinoma cell line Caco-2. Carcinogenesis 22 1061-1067.
230. I.K. Wang, S.Y. Lin-Shiau and J.K. Lin (2000) Suppression of invasion and MMP-9 expression in NIH 3T3 and v-H-Ras 3T3 fibroblasts by lovastatin through inhibition of ras isoprenylation. Oncology 59 245-254.
231. W. Wang and R.J.B. Macaulay (2003) Cell-cycle gene expression in lovastatin-induced medulloblastoma apoptosis. Can J Neurolog Sci 30 349-357.
232. X. Wang, R. Sato, M.S. Brown, X. Hua and J.L. Goldstein (1994) SREBP-1, a membrane-bound transcription factor released by sterol-regulated proteolysis. Cell 77 53-62.
233. D. Westfall, N. Aboushadi, J.E. Shackelford and S.K. Krisans (1997) Metabolism of farnesol: phosphorylation of farnesol by rat liver microsomal and peroxisomal fractions. Biochem Biophys Res Commun 230 562-568.
234. D. Wolf and V. Rotter (1985) Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL-60 cells. Proc Natl Acad Sci USA 82 790-794.
235. S. Yachnin, D. Toub and V. Mannickarottu (1984) Divergence in cholesterol biosynthetic rates and 3-hydroxy-3-methylglutaryl-CoA reductase activity as a consequence of granulocyte versus monocyte-macrophage differentiation in HL-60 cells. Proc Natl Acad Sci USA 81 894-897.
236. M. Yaguchi, K. Miyazawa, T. Katagiri, J. Nishimaki, M. Kizaki, K. Tohyama and K. Toyama (1997) Vitamin K2 and its derivatives induce apoptosis in leukemic cells and enhance the effect of alltrans-retinoic acid. Leukemia (Basingstoke) 11 779-787.
237. M. Yaguchi, K. Miyazawa, M. Otawa, T. Katagiri, J. Nishimaki, Y. Uchida, O. Iwase, A. Gotoh, Y. Kawanishi and K. Toyama (1998) Vitamin K2 selectively induces apoptosis of blastic cells in myelodysplastic syndrome: Flow cytometric detection of apoptotic cells using APO2.7 monoclonal antibody. Leukemia (Basingstoke) 12 1392-1397.
238. Y.A. Yang, W.F. Han, P.J. Morin, F.J. Chrest and E.S. Pizer (2002) Activation of fatty acid synthesis during neoplastic transformation: role of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Exp Cell Res 279 80-90.
239. Y.A. Yang, P.J. Morin, W.F. Han, T. Chen, D.M. Bornman, E.W. Gabrielson and E.S. Pizer (2003) Regulation of fatty acid synthase expression in breast cancer by sterol regulatory element binding protein-1c. Exp Cell Res 282 132-137.
240. Y. Yarden (2001) Biology of HER2 and its importance in breast cancer. Oncology 61 1-13.
241. E.M. Yazlovitskaya and G. Melnykovych (1995) Selective farnesol toxicity and translocation of protein kinase C in neoplastic HeLa-S3K and non-neoplatic CF-3 cells. Cancer Lett 88 179-183.
242. S.G. Yu, N.M. Abuirmeileh, A.A. Qureshi and C.E. Elson (1994) Dietary β-ionone suppresses hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase activity. J Agric Food Chem 42 1493-1496.
243. F.L. Zhang and P.J. Casey (1996) Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem 65 241-269.
244. J. Zhang, J. Zhang, Y. Zhao, H. Shi, S. Zhu and M. Cai (1999) Effects of beta-carotene on apoptosis and cell cycle of leukemic cell line HL-60. Acta Nutrimenta Sinica 21 401-404.
245. J. Zujewski, I.D. Horak, C.J. Bol, R. Woestenborghs, C. Bowden, D.W. End, V.K. Piotrovsky, J. Chiao, R.T. Belly, A. Todd, W.C. Kopp, D.R. Kohler, C. Chow, M. Noone, F.T. Hakim, G. Larkin, R.E. Gress, R.B. Nussenblatt, A.B. Kremer and K.H. Cowan (2000) Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol 18